Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.

Cheung, N K; Lazarus, H; Miraldi, F D; Abramowsky, C R; Kallick, S; Saarinen, U M; Spitzer, T; Strandjord, S E; Coccia, P F; Berger, N A

Cheung, N K; Lazarus, H; Miraldi, F D; Abramowsky, C R; Kallick, S; Saarinen, U M; Spitzer, T; Strandjord, S E; Coccia, P F; Berger, N A.

J Clin Oncol ; 5(9): 1430-40, 1987 Sep.

Article in En | MEDLINE | ID: mdl-3625258

Subject(s)

Antibodies, Monoclonal/therapeutic use; Gangliosides/immunology; Melanoma/therapy; Neuroblastoma/therapy; Adolescent; Adult; Antibodies, Monoclonal/adverse effects; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infant; Male; Middle Aged

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Gangliosides / Melanoma / Antibodies, Monoclonal / Neuroblastoma Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1987 Type: Article

Search on Google

XML

PubMed Links